Last checked at 1 Mar 2021 07:00
ReNeuron Group plc
("ReNeuron" or the "Company")
Â
Block Listing Review and Total Voting Rights
Â
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
Â
Name: | ReNeuron Group plc |
Name of Scheme: | ReNeuron Share Option Schemes |
Period of Return: | From 1 September 2020 to 28 February 2021 |
Balance of unallotted securities under scheme(s) from previous return: | 674,687 Ordinary Shares (of 1p each) Â |
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for): | N/A |
Less: Number of securities issued/allotted under scheme(s) during period | 11,000 |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 663,687 Ordinary Shares |
Number and class of securities originally admitted and the date of admission: | 20,000 ordinary shares on 13 May 2010 |
Â
Â
Total Voting Rights
At 28 February 2021, the Company had 56,855,705 Ordinary Shares in issue, each carrying one voting right.
Â
As the Company holds no ordinary shares in treasury, the figure of 56,855,705 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Â
Contacts:
Â
ReNeuron | www.reneuron.com/investors | |
Olav Hellebø, Chief Executive Officer | Via Walbrook PR | |
Michael Hunt, Chief Financial Officer | Â | |
 |  | |
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace | +44 (0)20 7710 7600 Â | |
Allenby Capital Limited (Joint Broker) | +44 (0)20 3328 5656 | |
James Reeve/George Payne (Corporate Finance) | ||
Tim Sohal (Sales & Corporate Broking) | ||
 |  | |
Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or reneuron@walbrookpr.com | |
Paul McManus, Alice Woodings | +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
Â
Â
Â
About ReNeuron
Â
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Â